Shots:

• The BT designation follows the P-IIb Trial in patients with IFD or probable invasive aspergillosis (IA) and either refractory disease- resistance- or intolerance to available agents
• The study resulted in well tolerable results across more than 10 years of patient dosing days with a median therapy duration of 12 wks.
• Olorofim is first antifungal agent targeted to treat invasive fungal mold infections such as azole-resistant aspergillosis- scedosporiosis- lomentosporiosis- and other rare mold infections and is being developed as IV and oral formulation

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: F2G